Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

Journal:

Journal of Clinical Endocrinology & Metabolism

Published:

2025-12-10

DOI:

10.1210/clinem/dgaf655

Affiliations:

11

Authors:

22

Go to article

Institutions	Authors	Share
University Medical Center Mainz, JGU, Germany	9.500000	0.43
Novartis, Switzerland	2.500000	0.11
Bürgerhospital Frankfurt, Germany	2.000000	0.09
Essen University Hospital, Germany	2.000000	0.09
Novartis Pharmaceuticals Corporation, United States of America (USA)	2.000000	0.09
University Medical Center Freiburg, Germany	2.000000	0.09
University Medical Center Göttingen (UMG), Germany	2.000000	0.09

Interested in Clinical Sciences?